Astrazeneca ADR Stock
-
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -0.430% | 3.084% | -7.327% | 30.726% | 11.962% | 43.558% | 20.774% |
| Bayer AG ADR | 2.160% | -3.077% | -11.682% | 68.750% | 7.386% | -31.522% | -27.863% |
| Novartis AG ADR | -0.770% | 1.976% | -9.790% | 24.638% | 8.861% | 54.306% | 73.154% |
News
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Since the start of the year, investors have been vacating U.S. stocks and exchange-traded funds (ETFs) in a broad-based, risk-off strategy that has benefited safe-haven assets like gold and silver
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable

